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Advanced head and neck squamous cell carcinoma (HNSCC) remains a therapeutic challenge due to the 
development of therapy resistance. Several studies have implicated the development of cancer stem cells as a 
possible mechanism for therapy resistance in HNSCC. Heat shock protein 90’s (Hsp90’s) molecular chaperone 
function is implicated in pathways of resistance in HNSCC. Therefore, in the present study, we investigated the 
efficacy of novel C-terminal Hsp90 inhibitors (KU711 and KU757) in targeting HNSCC cancer stem cells (CSCs). 
Treatment of HNSCC human cell lines MDA1986, UMSCC 22B, and UMSCC 22B cisplatin-resistant cells with the 
KU compounds indicated complete blockage of self-renewal for the resistant and parent cell lines starting from 20 
μM KU711 and 1 μM KU757. Dose-dependent decrease in the cancer stem cell markers CD44, ALDH, and CD44/ 
ALDH double-positive cells was observed for all cell lines after treatment with KU711 and KU757. When cells were 
treated with either drug, migration and invasion were downregulated greater than 90% even at the lowest 
concentrations of 20 μM KU711 and 1 μM KU757. Western blot showed N90% reduction in client protein 
“stemness” marker BMI-1 and mesenchymal marker vimentin, as well as increase in epithelial marker E-cadherin 
for both cell lines, indicating epithelial to mesenchymal transition quiescence. Several CSC-mediated miRNAs that 
play a critical role in HNSCC therapy resistance were also downregulated with KU treatment. In vivo, KU
compounds were effective in decreasing tumor growth with no observed toxicity. Taken together, these results 
indicate that KU compounds are effective therapeutics for targeting HNSCC CSCs. 
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Despite the introduction of newer therapeutic protocols, mortality 
rates associated with head and neck squamous cell carcinoma 
(HNSCC) have remained largely unchanged over the last four 
decades [1]. Concurrent radiation and chemotherapy have become 
the standard for adjuvant therapy after surgical ablation, as well as the 
definitive treatment of HNSCC in select cases. Systemic 
platinum-based chemotherapy, namely, cisplatin, remains a first-line 
agent due to its radiosensitizing and cytotoxic effects [2,3]. 
Unfortunately, chemotherapy and radiation-based treatments have 
been associated with significant toxicity, particularly in patients 
receiving concurrent chemoradiotherapy [4]. HNSCC has shown 
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resistance requiring dose escalation and resultant toxicities continues to be 
problematic, highlighting a need for the development of novel therapies 
that effectively treat this disease and its cisplatin resistance [5,6]. 
Cancer stem cells (CSCs) represent a subpopulation of cells within 
a tumor that have the ability of self-renewal and regeneration. Recent 
literature suggests that this population of cells is thought to 
significantly contribute to tumor proliferation, invasion, metastatic 
potential, and resistance to drug therapy [7–11]. This subpopulation 
may lie quiescent for periods of time as well as harbor protective 
mechanisms against cellular damage, and is felt to be responsible for 
the majority of tumor growth and metastatic potential in HNSCC 
[11,12]. Furthermore, CSCs have been shown to contribute to 
resistance against chemotherapeutic agents, including platinum-based 
regimens along with external beam radiation [5,13]. Nor et al. using 
an HNSCC xenograft model observed that cisplatin treatment 
increased the fraction of CSCs as defined by the ALDHhigh/CD44high 
populations, again implicating this cellular subpopulation in resistance 
to current standard-of-care therapies [14]. Thus, it seems to reason that 
in order to more effectively treat or abrogate chemo- and drug resistance 
in HNSCC, this process should involve some level of targeting of the 
CSC population. 
Heat shock protein (Hsp) 90 is a molecular chaperone protein that 
regulates several “client” proteins involved in cancer development, 
including proteins involved in pathways critical for cell growth, 
invasiveness, and survival [15]. Numerous proteins implicated as 
critical for CSCs’ development are also dependent on Hsp90. This 
suggests a high therapeutic potential for Hsp90 inhibitors as they can 
simultaneously suppress multiple oncogenic pathways involving the 
bulk tumor cell population of a cancer as well as its CSCs. Use of first-
and second-generation Hsp90 inhibitors targeting the N-terminal 
domain of the chaperone was restricted due to dose-limiting toxicity, 
resulting mainly from activation of the heat shock response leading to 
induction of compensatory proteins (e.g., Hsp70) with prosurvival 
effects [16]. Thus, early-generation N-terminal Hsp90 inhibitors 
have not progressed beyond early-phase clinical trials despite showing 
potent anticancer effects. To address limitations of N-terminal Hsp90 
inhibitors, our group has developed potent, novel Hsp90 inhibitors 
targeting the carboxy terminus of the chaperone which blocks Hsp90 
chaperone function without concurrently upregulating Hsp70 and its 
prosurvival effects, thus avoiding this key limitation of N-terminal 
inhibitors [17–21]. These compounds have potential to act 
synergistically with current standard-of-care therapies and prolong 
or prevent development of drug resistance [16,22]. Hence, we 
hypothesized that C-terminal Hsp90 inhibitors (especially our lead 
compounds KU711 and KU757, chosen for their potency and 
selectivity for cancer cells; structures in Supplemental Figure 1) can 
inhibit key CSC functions including migration, invasion, 
self-renewal, and epithelial to mesenchymal transition (EMT); can 
target the miRNAs involved in CSC function; and can reduce tumor 
growth of HNSCC xenografts. 
Materials and Methods 
Cell Culture 
The validated HNSCC cell line UMSCC 22B was generated at the 
Michigan Otolaryngology and Translational Oncology Laboratory 
and graciously donated by Dr. Thomas Carey. UMSCC 22B-cis, a 
kind gift from Dr. Jacques Nor, University of Michigan, Ann Arbor, is a cisplatin-resistant line generated by co-culturing UMSCC 22B 
with increasing concentrations of cisplatin in vitro up to 12 μM 
concentration, as previously described [14]. The validated HNSCC 
cell line MDA-1986 was graciously donated by Dr. Jeffrey Myers 
(University of Texas, M.D. Anderson Cancer Center, Houston, TX). 
Cells were grown and maintained in Dulbecco's modified Eagle's 
medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% 
fetal bovine serum (Sigma-Aldrich) and 1% combination of penicillin 
and streptomycin (Sigma-Aldrich) in a 37°C humidified atmosphere 
of 5% CO2 in air. Drug compounds used in these experiments 
included two C-terminal Hsp90 inhibitors, KU711 and KU757, and 
these were obtained from Dr. Brian S. J. Blagg (University of Notre 
dame, Indiana, IN). Finally, a standard N-terminal Hsp90 inhibitor, 
17-AAG, was obtained from Sigma-Aldrich. 
Orosphere Formation Assay 
MDA-1986, UMSCC 22B, and UMSCC 22B-cis cells were plated 
at 100 cells/well in a 96-well ultralow attachment plate (Corning, 
Corning, NY) in low-glucose DMEM (Life Technologies) with 
varying concentrations of KU711, KU757, 17-AAG, and cisplatin 
[up to five times their half-maximal inhibitory concentration (IC50) 
values[. Cells were cultured for 10 to 14 days, and orosphere 
formation (N25 cells) was assessed in each well using light microscopy. 
ALDEFLOUR Assay/Flow Cytometry 
UMSCC 22B, UMSCC 22B-cis, and MDA-1986 cells were 
treated and collected as described for Western blot analysis and 
evaluated for ALDH activity using the ALDEFLOUR assay kit as per 
the manufacturer's instructions (Stem Cell Technologies, Vancouver, 
BC, Canada). CD44-positive populations were detected by flow 
cytometry using APC conjugated CD44. Flow cytometric analysis 
was conducted on a CyAn ADP analyzer (Beckman Coulter, Brea, 
CA). DAPI staining was used to exclude dead cells from analysis. 
Western Blot/EMT 
Cells were grown to 60% to 80% confluence and treated for 24 
hours at 20 to 40 μM KU711 or 1 to 2.5 μM KU757 (1-2× and 
1-2.5× IC50), 1 μM 17-AAG, or 2 μM cisplatin. Treated cells were 
collected and resuspended in lysis buffer, and protein concentrations 
were determined using the BSA protein assay (Thermo Fisher 
Scientific, Waltham, MA). Immunoblotting was performed by 
methodology published previously [23]. BMI-1, E-cadherin, and 
vimentin antibodies were purchased from Cell signaling Technology 
(CST, Danvers, MA), β-actin from Millipore (EMD Millipore, 
Billerica, MA), and donkey anti-rabbit IgG HRP (1: 3000) and goat 
anti-mouse IgG HRP (1: 3000) secondary antibodies from 
Santa-Cruz. Membranes were developed with either SuperSignal 
West PICO or FEMTO (Thermo Fisher Scientific, Waltham, MA) 
for 5 minutes and visualized by enhanced chemiluminescence and 
captured on autoradiography film (Molecular Technologies, St. 
Lewis, MO) on a Konica Minolta SRX 101A developer (Ramsey, 
NJ). Actin levels were assessed as a housekeeping gene to ensure equal 
loading and transfer of proteins. Studies were replicated for accuracy. 
Migration and Invasion Assay 
UMSCC 22B and UMSCC 22B-cis cell lines were collected and 
resuspended in serum-free DMEM with penicillin/streptomycin and 
20 to 40 μM KU711 or 1 to 2.5 μM KU757 or 1 μM 17-AAG or 2 
μM cisplatin. Equal numbers of cells were plated onto either standard 
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Figure 1. (A and B) Orosphere formation assay. HNSCC cells were treated with varying concentrations of Hsp90 inhibitors in an ultralow 
attachment plates. Formation of spheres was counted by light microscopy, and representative sphere images are presented. or Matrigel-coated upper wells of the 8-μm polycarbonate Boyden 
chambers (Corning) with DMEM supplemented with 10% fetal 
bovine serum as lower wells’ chemoattractant. Chambers were 
incubated for 24 hours at 37°C; migrated cells were fixed in 2% 
paraformaldehyde and stained with 1% crystal violet in 20% 
methanol for 20 minutes. After staining, membranes were washed 
in water, and the remaining upper-well cells were removed using a 
cotton swab. Migration using standard chambers and invasion with 
Matrigel-coated chambers were quantified using light microscopy as 
number of cells per high-powered field. 
miRNA Analysis 
UMSCC 22B and 22B cisplatin cells were treated with either 
KU711 at 20 μM or KU757 at 1 μM for 24 hours, and RNA was 
isolated using Qiagen miRNeasy kit as per the manufacturer's 
protocol. The RNA was quantified using NanoDrop, and approx­
imately 500 ng of the RNA was reverse transcribed using the miScript 
II RT Kit. The cDNA was used as a template in real-time PCR with a 
human miScript miRNA cancer stem cell PCR Array and the 
miScript SYBR Green PCR Kit (Qiagen). The data were normalized 
to global CT mean of expressed miRNA, and the fold difference of 
the target genes’ expression compared to the control group was 
calculated by the 2−ΔΔCT method. 
HNSCC Xenograft and Immunohistochemistry 
In vivo efficacy of the Ku compounds KU711 and KU757 was 
assessed using a murine buccal tumor model. The buccal mucosa was injected with 1 × 106 cells, and tumor treatment was initiated when 
the tumors reached the size of approximately 4 mm2 in diameter; the 
mice were randomized into control, KU711, KU757, 17-AAG, and 
cisplatin groups. Mice were dosed intraperitoneally with 5 mg/kg of 
KU757 and 50 mg/kg of 17-AAG twice weekly and with KU711 and 
cisplatin at 5 mg/kg every day for 3 weeks. Tumor burden was 
measured using caliper measurement of greatest tumor dimension at 
twice-per-week intervals. All procedures were performed in accor­
dance with the University Committee for the Use and Care of 
Animals–approved protocol. 
Histologic evaluation was performed by a pathologist. To reduce 
bias, each group was blinded and randomly assigned with a group 
number (1-5). Signs suggestive of toxicity, such as chronic 
inflammation (defined by the presence of lymphocytes and plasma 
cells), cellular necrosis, and steatohepatitis, were assessed in the liver 
and kidney. “Normal” was assigned to specimens with essentially no 
pathology except for a small degree of inflammation comparable to 
what is seen physiologically. “Mild, moderate, or severe” was assigned 
to specimens with a less than 10%, 10% to 50%, and greater than 
50% increase in inflammatory cells compared to the physiologic 
state, respectively. Percent proliferation was determined via positive 
nuclear staining by immunohistochemical stain Ki67. Ki67-positive 
neoplastic cells and Ki67-negative cells were counted in five 
representative high-power microscopic fields in each specimen, 
and the percent positivity was calculated for each high-power 
field. The final percent was calculated by taking the average of the 
five values. 
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Figure 2. (A) Analysis of cancer stem cell markers CD44 and ALDH after treatment of HNSCC cells with HSp90 inhibitors KU711, KU757, 
and 17-AAG for 24 hours by flow cytometry analysis. (B) Representative flow cytometry data. Statistical Analysis 
Significance (set as 95%, P b .05) between treatment groups in flow 
cytometry, orosphere assay, and Boyden chamber assays was identified 
using Student’s 2-tailed, unpaired t test. Migration and invasion data were proportionally adjusted for treatment-related cell death using 
corresponding viability data from DAPI exclusion by flow cytometry. 
Each experiment was done in triplicate and was replicated to ensure 
accuracy. The data values are presented as mean ± standard deviation. 
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Figure 3. (A and B) Migration and invasion of HNSCC cells using Boyden chamber assay after 24-hour drug treatment with HSP90 
inhibitors. Cell line MDA-1986 is used in panel A. Results 
Hsp90 Inhibitors Block Self-Renewal 
Self-renewal of tumors, a function attributed to CSCs, was 
analyzed by orosphere formation assay (Figure 1, A and B). 
MDA1986, UMSCC 22B, and UMSCC 22B-cis experienced 
inhibition of orosphere formation after treatment with both 
C-terminal Hsp90 inhibitors. Significant inhibition was observed 
even with the starting concentrations of 10 μM KU711 and 1 μM 
KU757 (P b .001 vs control), and complete blockage of orosphere 
formation was seen at concentrations of 20 μM KU711 and 2.5 μM 
KU757. Orosphere formation was increased when both the parent 
and cisplatin-resistant UMSCC 22B cell lines were treated with 
cisplatin, relative to control (P b .001) (Figure 1B). Similar trends 
were observed when the same agents were used to treat the oral cavity 
squamous cell carcinoma cell line MDA-1986 (P b .001) (Figure 1, Figure 4. EMT and changes in the levels of BMI-1 were evaluated 
by immunoblot analysis. Actin was used as a loading control. A and B). N-terminal Hsp90 inhibitor 17-AAG treatment resulted in 
inhibition of orosphere formation to a lesser extent in lines 
MDA-1986 and UMSCC 22B, and inhibition was not statistically 
significant in UMSCC 22B-cis cells (Figure 1B). 
Hsp90 Inhibitors Target Cancer Stem Cell Markers 
HNSCC cells from each cell line were evaluated for CSC markers 
using CD44 expression and ALDH activity. ALDH activity was 
assessed by ALDEFLOUR assay. Cell lines UMSCC 22B, UMSCC 
22B-cis, and MDA-1986 were treated with two C-terminal Hsp90 
inhibitors, KU711 and KU757, as well as one N-terminal Hsp90 
inhibitor, 17-AAG. As seen from Figure 2, A and B, a dose-dependent 
decrease in ALDH+ cells, CD44+ cells, and double-positive (ALDH+/ 
CD44+) cells was observed for all cell lines treated with 20 to 40 μM 
KU711 and 1.0 to 2.5 μM KU757  (P b .001 relative to control), 
indicating decreased CSC cell populations following treatment. In 
contrast, each of these cell populations was increased or unchanged 
when treated with cisplatin alone (Figure 2, A and B), in agreement 
with previously described findings by Nor et al. [14]. Finally, ALDH+, 
CD44+, double-positive population changes relative to control were 
variable when cells were treated with 17-AAG. Even though 17-AAG 
treatment decreased the ALDH-positive population, the levels of 
CD44-positive or double-positive cells did not show significant 
difference compared to control cells (Figure 2, A and B). 
BMI1, a known marker of “stemness,” was evaluated for inhibition 
by Hsp90 inhibitors since it is known to be a client protein of Hsp90 
chaperone function (Figure 4). In MDA-1986 cells treated with 
KU711 and KU757, BMI1 expression was decreased by up to 65% 
and 31%, respectively. BMI1 concentration decreased by 58% when 
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Figure 5. UMSCC 22B cells were treated with cisplatin, KU711, or KU757 for 24 hours. The cDNA from the cells was used in miScript 
miRNA array for cancer stem cells. Greater than two-fold changes in miRNA expression compared to controls are presented in the figure. treated with 1 μM 17-AAG. Finally, cisplatin treatment resulted in 
slight increase in BMI1 expression relative to control (consistent with 
what has been reported by Nor et al.) [14]. 
Hsp90 Inhibitors Decrease Migration, Invasion, and EMT 
To examine whether inhibition of this HNSCC CSC population 
can lead to decreases in invasive potential, we next analyzed migration 
and invasion by Boyden chamber assay. Additionally, we evaluated 
EMT transition by Western blotting for epithelial and mesenchymal 
markers such as vimentin and E-cadherin. Boyden chambers were 
used to determine migration and invasion after 24 hours of treatment 
each with Hsp90 inhibitors (KU711, KU757, or 17-AAG). In all 
HNSCC cell lines tested, there was a significant decrease in both 
migration and invasion after treatment with KU711 or KU757 
(Figure 3, A and B). In UMSCC 22B and UMSCC 22B-cis, Hsp90 
inhibition by 20 μM KU711, 2.5 μM KU757, and 1 μM 17-AAG 
each resulted in a greater than 90% decrease in EMT (P b .001 vs 
control). Statistically significant inhibition of migration and invasion 
was seen with cisplatin therapy as well, though to a lesser degree of 
approximately 40% and 60%, respectively. Migration and invasion 
were inhibited by N90% in MDA-1986 cells when treated at higher 
concentrations of 40 μM KU711 and 2.5 μM KU757, while 
17-AAG resulted in only a 40% decrease in migration and N90% 
decrease in invasion (P b .001). 
We next evaluated E-cadherin expression as a marker of epithelial 
differentiation. In MDA-1986 cells treated with KU711, E-cadherin expression was increased by 50% to 53%, while there was no 
significant change observed with cisplatin, 17-AAG, or KU757 
treatment compared to controls (Figure 4). Likewise, vimentin 
expression was evaluated as a marker of mesenchymally derived cells. 
Vimentin was decreased under all treatment conditions relative to 
control, indicating decreased EMT. This trend was greater with 
Hsp90 inhibitor treatment relative to cisplatin treatment as most of 
the vimentin expression was attenuated completely at higher 
concentrations of KU711, KU757, and 17-AAG (Figure 4). 
Downregulation of miRNAs Implicated in Treatment 
Resistance Pathways 
Aberrant miRNA expressions are implicated in CSC functions 
such as self-renewal, differentiation, metastasis development, and 
tumor recurrence [24].Hence, in an effort to identify the 
CSC-related miRNAs that are modulated by our novel HSP90 
inhibitors, KU711 and KU757, we have used miScript miRNA array 
for identification of cancer stem cells (Qiagen, Germantown, MD). 
The results from our study showed that several miRNAs that are 
known to be upregulated in HNSCC such as miRNA 15b, 16, 17, 
107,20a, 106b, 128, and 425 are all downregulated after treatment 
with our C-terminal Hsp90 inhibitors but are not significantly 
affected by cisplatin treatment (Figure 5) [25,26].Similarly, several of 
the downregulated miRNAs in HNSCC such as 223, 299, 145, 
302a, 494, 409, and 128 are upregulated only when these cancer cells 
are treated with KU711 and KU757 but not with cisplatin treatment 
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Table 1. (A) Genes Regulated by miRNAs That are Modulated After Treatment of UMSCC22B 
Cells With Cisplatin; (B) Genes Regulated by miRNAs That are Modulated After Treatment of 
UMSCC22B Cells With KU Compounds 
A 
SOX11 hsa-miR-296-5p, hsa-miR-137, hsa-miR-141-3p 
MAP3K12 hsa-miR-130a-3p, hsa-miR-122-5p, 146b-5p 
FOXK2 hsa-miR-146b-5p, hsa-miR-155-5p, hsa-miR-125b-5p, hsa-miR-130a-3p, 
hsa-miR-409-3p 
SMAD4 hsa-miR-130a-3p, hsa-miR-125b-5p, hsa-miR-409-3p, hsa-miR-146b-5p 
BCL11A hsa-miR-146b-5p, hsa-miR-130a-3p, hsa-miR-125b-5p 
E2F2 hsa-miR-125b-5p, hsa-miR-409-3p, hsa-miR-146b-5p 
B 
CCND2 hsa-miR-299-5p, hsa-miR-302a-3p, hsa-miR-494-3p, hsa-miR-145-5p, 
hsa-miR-320d 
IGF1R hsa-miR-223-3p, hsa-miR-145-5p, hsa-miR-494-3p, hsa-miR-320d 
CDK6 hsa-miR-320d, hsa-miR-494-3p, hsa-miR-145-5p 
CTNND2 hsa-miR-636, hsa-miR-494-3p, hsa-miR-122-5p 
CUL3 hsa-miR-302a-3p, hsa-miR-636, hsa-miR-494-3p 
XIAP hsa-miR-105-5p, hsa-miR-320d, hsa-miR-494-3p 
BCL2L11 hsa-miR-302a-3p, hsa-miR-494-3p, hsa-miR-105-5p 
IGF2BP1 hsa-miR-494-3p, hsa-miR-302a-3p, hsa-miR-150-5p 
APC hsa-miR-494-3p, hsa-miR-150-5p, hsa-miR-223-3p 
EIF5 hsa-miR-494-3p, hsa-miR-302a-3p 
TCF4 hsa-miR-105-5p, hsa-miR-155-5p, hsa-miR-145-5p, hsa-miR-636 
KRAS hsa-miR-105-5p, hsa-miR-155-5p, hsa-miR-134-5p, hsa-miR-409-3p 
SMAD2 hsa-miR-302a-3p, hsa-miR-486-5p, hsa-miR-105-5p, hsa-miR-155-5p 
XIAP hsa-miR-105-5p, hsa-miR-320d, hsa-miR-494-3p 
BCL2L11 hsa-miR-302a-3p, hsa-miR-494-3p, hsa-miR-105-5p 
SLC12A2 hsa-miR-636, hsa-miR-105-5p 
TP53INP2 hsa-miR-105-5p, hsa-miR-302a-3p 
BCL2L2 hsa-miR-1207-5p, hsa-miR-105-5p 
NOVA1 hsa-miR-107, hsa-miR-146b-5p, hsa-miR-96-5p, hsa-miR-128-3p, hsa-let-7c-5p, 
hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-222-3p, hsa-miR-221-3p 
NRAS hsa-miR-146b-5p, hsa-let-7c-5p, hsa-let-7a-5p, hsa-let-7f-5p 
ZNRF3 hsa-miR-146b-5p, hsa-miR-107, hsa-miR-16-5p, hsa-miR-15b-5p 
BCL11A hsa-miR-146b-5p, hsa-miR-107, hsa-miR-96-5p (Figure 5) [25,26]. The miRNA 516 and miRNA 122 and 155 
implicated in HNSCC are modulated by cisplatin as well as by KU 
compounds. These results indicate that cisplatin is able to modify 
only three miRNAs that are implicated in HNSCC, whereas our 
novel c-terminal Hsp90 inhibitors KU711 and KU757 are able to 
alter several miRNAs that are dysregulated in HNSCC. Further 
validation of these miRNAs is needed to better understand the exact 
mechanisms through which these miRNAs target cancer stem cells 
following treatment with KU711 and KU757. Additionally, analysis 
of the genes regulated by the miRNAs by TargetScan indicates that 
proteins  such  as  MAPK, FOXX2, SOX11,  SMAD4, BCL11A,  and  
E2F2 are regulated by these miRNAs after treatment with cisplatin, 
whereas treatment with KU711 and KU757 regulates several 
genes involved in cell cycle, proliferation, MAPK, and β-catenin 
pathways (Table 1). 
Antitumor Effects with Decreased Toxicities 
In vivo treatment using a murine buccal tumor model showed 
strong antitumor effects for KU711 and KU757 treatment, with 
significant decrease in tumor burden up to 6 weeks of treatment 
(Figure 6A). Steady and continued tumor growth was seen in the 
control and cisplatin treatment groups (Figure 6A). Mice treated with 
17-AAG did show early response to treatment but did not survive 
beyond week 5 (Figure 6A). In each group, treatment effects were 
seen around 4 weeks of treatment, presumably when drug 
concentrations had reached an effective systemic concentration. 
On histopathology, KU711, KU757, and 17-AAG showed 
decrease in the proliferation marker Ki67 by 15%, 15%, and 5% to 10% from the control value of 30%, indicating the efficacy of the 
drugs in preventing proliferation. But ki67 percentage was increased 
to 50 from the control value of 30 for cisplatin treatment which is 
consistent with our tumor growth studies (Figure 6B and Table 2). 
17-AAG experimental group alone showed a mild increase (less than 
10%) in periportal lymphoplasmacytic infiltration, while all other 
groups showed a small, physiologic amount of inflammation in the 
liver. Similarly, cisplatin showed less than 10% increase in 
lymphocytic inflammation in the kidney, predominately in the 
inner medulla, while other groups showed no changes compared to 
control groups (Figure 6B and Table 2). 
Discussion 
Despite introduction of platinum-based chemotherapy regimens, 
survival outcomes for advanced HNSCC remain poor over the last 
few decades [1]. Cisplatin remains the mainstay of most commonly 
used chemotherapeutic regimens in HNSCC, though with well-
recognized toxicity to the peripheral nerves, kidneys, and hearing. 
Treatment failures in advanced HNSCC treated with primary 
chemoradiation or surgery with adjuvant chemoradiotherapy are 
attributable at least in part to tumor resistance. This study builds on 
previous evidence that the CSC population is likely implicated in 
HNSCC aggressiveness (invasion and migration), tumorgenicity, and 
resistance mechanisms (e.g., cisplatin resistance). We now demon­
strate that novel C-terminal Hsp90 inhibitors target this CSC 
subpopulation of cells as noted by inhibition of orosphere formation 
and expression of the cancer stem cell markers ALDH and CD44 as 
well as blocking migration, invasion, and tumor growth without 
significant toxicity associated with cisplatin or 17-AAG. 
Hsp90 inhibitors were initially developed with the rationale that 
Hsp90 is overexpressed in tumor cells and serves as a molecular 
chaperone to many “client” proteins that are overexpressed in models 
of carcinogenesis [27]. Indeed, these inhibitors accumulate consid­
erably more efficiently in tumor cells relative to normal tissue, further 
suggesting that these novel inhibitors are likely to preferentially target 
the tumor cell population and CSC subpopulation [15]. Our group 
focused on two novel C-terminal inhibitors, KU711 and KU757, 
which have shown potency and selectivity for HNSCC in vitro as well 
as recently in vivo. While cisplatin has been shown to increase the 
CSC population in HNSCCs in addition to other proposed 
mechanisms of resistance [14], our observation with novel 
C-terminal Hsp90 inhibitors in this study shows the opposite effect 
on CSCs. In this study, a dose-dependent decrease in ALDH+ cells, 
CD44+ cells, and double-positive (ALDH+/CD44+) cells was 
observed for all cell lines treated with both C-terminal Hsp90 
inhibitors, while results were more variable with 17-AAG. Of note, 
populations of CSCs (as measured by CD44+/ALDH+ double-
positive cells) varied across cell lines when treated with the N-terminal 
inhibitor 17-AAG, and this could represent variable upregulation of 
the prosurvival heat shock response upon 17-AAG treatment at the 
chosen dose. As noted, early-generation N-terminal Hsp90 inhibitors 
have failed to progress beyond phase II clinical trials due to 
dose-related toxicity from induction of the compensation 
Hsp70-mediated prosurvival heat shock response [17]. We have 
noted that our C-terminal Hsp90 inhibitors avoid upregulation of the 
heat shock response, as indicated by expression of Hsp70 [23]. 
Additionally, our group has previously shown that C-terminal Hsp90 
inhibitors had both antitumor efficacy and improved toxicity profiles 
compared with standard agents in in vitro and in vivo (orthotopic) 
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Figure 6. (A and B) HNSCC xenograft was developed using MDA-1986. (A) Tumor volume curves, Kaplan-Meier survival curves, and 
changes in mouse weight during treatment. (B) Histopathology evaluation of HNSCC xenografts showing improved toxicity profile with 
KU compound treatment. HNSCC models [28]. HNSCC cell treatment was shown to induce 
apoptosis and downregulate oncogenic client proteins (such as Akt 
and Raf-1), and animals treated with Hsp90 inhibitors showed 
comparable tumor response with decreased toxicity (body score and 
weight loss) compared to cisplatin chemotherapy. Furthermore, we 
had shown that our novel C- terminal Hsp90 inhibitors effectively 
target CSCs in HNSCC cell lines in vitro for differentiated and 
anaplastic thyroid cancer models, resulting in decreased CSC function 
and inhibition of migration/invasion [23]. Mclaughlin et al. recently 
proposed that Hsp90 inhibition (drug AUY922) sensitizes HNSCC 
to platin-based agents via modulation of DNA damage response 
mechanisms [29]. Taken together, these findings suggest that novel 
c-terminal Hsp90 inhibitors like KU711 and KU757 may have a 
potential adjunct role to current HNSCC treatments, especially in 
cases where cisplatin resistance warrants the use of alternatives with 
comparable efficacy. 
EMT is a critical step in a primary tumor's initiation of metastasis 
and progression. Our results demonstrate that C-terminal Hsp90 
inhibition also led to quiescence of EMT, as predicted by increased Table 2. Histopathology Evaluation of HNSCC Xenografts Showing Improved Toxicity Profile 
with KU Compound Treatment 
Group Control Cisplatin KU711 KU757 17-AAG 
Liver Normal Normal Normal Normal Mild periportal 
lymphoplasmacytic 
infiltration 
Kidney 
Ki67 (%) 
Normal 
30 
MILD lymphocytic inner 
medullary infiltrate 
50 
Normal 
15 
Normal 
15 
Normal 
5-10 E-cadherin expression with concurrent suppression of vimentin 
expression. Likewise, marked dose-dependent inhibition of migration 
and invasion was seen with both of our C-terminal Hsp90 inhibitors 
(KU711 and KU757). Taken together, these C-terminal inhibitors 
may have an important function to lower HNSCC's propensity 
toward development of regional and distant metastasis. This will 
require more in vivo studies for validation and further translation. 
Expression of Bmi1, a transcriptional regulator, CSC functional 
marker, and known client protein of Hsp90, was downregulated 
following treatment with C-terminal Hsp90 inhibitors. This 
downregulation was dose dependent with inhibitor KU757 and 
highly significant compared to controls (P b .0001). These findings 
are consistent with the hypothesis that these C-terminal Hsp90 
inhibitor drugs may be effective in overcoming mechanisms of 
cisplatin chemoresistance in HNSCC, as Nor et al. observed that 
cisplatin treatment resulted in subsequently induced expression of 
Bmi-1 [14]. Furthermore, Chen et al. showed that targeting Bmi1+ 
CSCs sensitized HNSCC tumors to cisplatin-based chemotherapy, 
further validating Bmi1 inhibition as a potential mechanistic 
approach to overcoming cisplatin resistance mechanisms [30]. 
Hsp90 inhibitors have also demonstrated additive or synergistic 
effects when used in combination with other chemotherapeutic 
agents [27]. Together, these findings further implicate the role the 
CSC population plays in the mechanisms of cisplatin resistance in 
HNSCC, suggesting that combination therapies with C-terminal 
Hsp90 inhibitors, particularly those with chemoradiotherapy­
sensitizing effects, may be critical in overcoming cisplatin treatment 
resistance in HNSCC. 
Several of the miRNAs that are implicated in the pathogenesis of 
HNSCC as well as in cancer stem cell function are all modulated by 
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suggests that compounds like KU757 or KU711 may have a role as 
potential therapeutics for targeting cancer stem cell populations that 
are responsible for therapy resistance and metastasis. Analysis of the 
pathways specifically targeted by miRNAs modulated by KU757 and 
KU711 (MAPK, cell cycle, and β-catenin) indicates that these 
C-terminal Hsp90 inhibitors target several CSC pathways involved in 
migration, invasion, and proliferation. Finally, the above data are 
promising in the context of concurrent in vivo experiments showing 
both antitumor effects and decreased treatment toxicity. Specifically, 
novel Hsp90 inhibitors avoid the well-described renal and hepatic 
toxicities associated with cisplatin and first-generation Hsp90 
inhibitors, respectively. Even though, treatment effects and toxicity 
were studied in the MDA-1986 cell line where additional cisplatin 
resistance was not generated, in vivo, the MDA-1986 tumor did show 
inherent cisplatin resistance as indicated by lack of response to 
cisplatin treatment (Figure 6). Overall, the results from our study 
clearly demonstrate that KU757 and KU711 may be an effective 
therapeutic strategy to targeting CSCs in HNSCC and to overcome 
cisplatin therapy resistance. Validation of these important findings 
with xenograft model using cisplatin-resistant cell lines may be 
warranted to advance these promising compounds translationally 
toward clinical applications in the future for this challenging disease. 
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